CTCBIO Inc. (KOSDAQ:060590)
3,110.00
+50.00 (1.63%)
At close: Sep 4, 2026
CTCBIO Revenue
CTCBIO had revenue of 33.69B KRW in the quarter ending June 30, 2026, with 9.00% growth. This brings the company's revenue in the last twelve months to 131.54B, up 17.21% year-over-year. In the year 2025, CTCBIO had annual revenue of 123.77B with 3.25% growth.
Revenue (ttm)
131.54B
Revenue Growth
+17.21%
P/S Ratio
0.57
Revenue / Employee
530.40M
Employees
248
Market Cap
74.36B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 123.77B | 3.89B | 3.25% |
| Dec 31, 2024 | 119.88B | -18.00B | -13.06% |
| Dec 31, 2023 | 137.88B | -27.33B | -16.54% |
| Dec 31, 2022 | 165.21B | 24.89B | 17.74% |
| Dec 31, 2021 | 140.32B | 10.29B | 7.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Psomagen | 60.70B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Naturalendo Tech | 22.79B |
| BIO-FD&C | 19.53B |
| PanGen Biotech | 14.18B |
| ADBiotech | 12.51B |
| EyeGene | 4.02B |
| SunBio,Inc. | 2.17B |